Calypso Medical Technologies Inc.
This article was originally published in Start Up
Calypso Medical Technologies aims to improve on the precision of cancer radiation therapy with technology that, like global positioning systems, tracks actual organ positioning in real-time, enabling radiation therapists to accurately target the tumor or treatment area and avoid hitting healthy organs.
You may also be interested in...
The Golden Age in Cancer Medtech Investing
Short of investing in the kinds of products that must demonstrate five-year survival rates, the field of cancer offers many near term investment opportunities, and large markets to support them. As noted in US Disease Incidence and Prevalence, a report recently published by the Medtech Insight division of FDC-Windhover, like many diseases, the incidence of cancer increases with age. More than 10.8 million people in the US have a history of cancer; and in 2008, at least 1.4 million more people will be diagnosed. According to the Medtech Insight report, breast cancer has the highest prevalence rate, followed by prostate and colorectal cancers.
Frazier's Commitment to Early-Stage Device Dealmaking Pays Off
Frazier Healthcare Ventures has never been one to faddishly follow the flow of money in or out of medical device investing, maintaining its commitment to invest in this space. Indeed, the firm recently shifted its focus to concentrate on more early-stage medical device deals, a strategy that appears to be paying off.
Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.